Pull to refresh
Logo
Daily Brief
Following Why Sign Up
InnoCare's oral eczema pill soficitinib clears late-stage trial

InnoCare's oral eczema pill soficitinib clears late-stage trial

New Capabilities

A selective TYK2 inhibitor aims to be the first of its class approved for atopic dermatitis

July 15th, 2026: Phase III trial meets primary endpoint

Overview

Updated Jul 15

Millions of people with severe eczema live with relentless itching and raw, inflamed skin. On July 15, 2026, InnoCare Pharma said its once-daily pill, soficitinib, hit the main goal of a late-stage trial in that group.

No TYK2 inhibitor has ever been approved for eczema anywhere. If InnoCare wins clearance, patients would get a targeted oral drug that calms the immune signal behind the disease, an option between messy creams and injected biologics.

Why it matters

A daily pill that clears severe eczema and eases itch would give patients an oral option that today only injections or broad immune drugs provide.

Questions about this story

Free account needed to ask — your question is kept and asked for you right after sign-up. Answers are public.

No questions yet — be the first to ask.

Key Indicators

579
Patients in Phase III trial
Size of the registrational study in moderate-to-severe atopic dermatitis.
0
TYK2 inhibitors approved for eczema
No drug in this class has cleared any regulator for atopic dermatitis.
64%
Phase II skin-clearance rate
Share reaching 75% skin improvement at week 4, versus 8% on placebo.
72%
Phase II itch relief
Share with a meaningful drop in itch by week 4, versus 16% on placebo.
400x
Selectivity over JAK2
How much more the drug blocks TYK2 than JAK2, aimed at fewer side effects.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Jasmine Cui
Jasmine Cui
Co-founder, Chairwoman and CEO of InnoCare Pharma
Leading InnoCare toward a regulatory filing for soficitinib
 Jinhua Xu
Jinhua Xu
Dermatologist, Huashan Hospital, Fudan University
Lead investigator on the published Phase II study

Organizations Involved

InnoCare Pharma
InnoCare Pharma
Biopharmaceutical Company
Developer of soficitinib, moving toward regulatory filing

A Beijing-based, commercial-stage drugmaker listed in Hong Kong and Shanghai, with three approved drugs and more than ten candidates in clinical testing.

Timeline

December 2023 July 2026

5 events Latest: July 15th, 2026 · 2 months ago
Tap a bar to jump to that date

  1. Phase III trial meets primary endpoint

    Latest Clinical Result

    InnoCare reported statistically significant skin improvement and no new safety signals, clearing the main hurdle toward approval.

  2. Phase II data published in JAMA Dermatology

    Publication

    Peer-reviewed results showed 64% reached major skin clearance at week 4, versus 8% on placebo.

  3. Vitiligo trial begins

    Pipeline Expansion

    InnoCare dosed the first patient in a soficitinib trial for vitiligo, widening the drug's use beyond eczema.

  4. First patient dosed in Phase III

    Trial Milestone

    The company began its registrational trial in China, the study needed to seek approval.

  5. Phase II trial meets its main goal

    Clinical Result

    InnoCare said soficitinib hit the primary endpoint in a mid-stage eczema study, clearing skin and easing itch.

Scenarios

1

InnoCare files for approval in China

Likely Resolves by End of 2027

Discussed by: InnoCare Pharma corporate statements; Dermatology Times

With the primary endpoint met and no new safety signals, InnoCare's stated next step is to finish the Phase III work and submit a marketing application. A filing to China's drug regulator would formally start the review that decides whether the pill reaches patients.

2

Soficitinib becomes first TYK2 pill cleared for eczema

Possible Resolves by Q2 2029

Discussed by: Dermatology Times; HCPLive coverage noting no TYK2 inhibitor is approved for the condition

If Chinese regulators approve soficitinib for atopic dermatitis, it would be the first drug in its class cleared for the disease anywhere. Approval would depend on the full Phase III package holding up under review, including longer safety follow-up.

3

Full Phase III data released at a conference or in a journal

Likely Resolves by Jul 15, 2027

Discussed by: InnoCare, which said detailed results will be presented later

The July announcement gave the headline result but withheld the numbers. InnoCare said it will present detailed data at scientific meetings and in publications. That release lets outside doctors judge how the pill compares with injected biologics and older JAK drugs.

4

InnoCare licenses soficitinib for markets outside China

Uncertain Resolves by Jul 15, 2028

Discussed by: Industry watchers tracking Chinese biotech out-licensing deals

Chinese drugmakers increasingly sell overseas rights to larger partners after strong trial data. A licensing deal for soficitinib would signal outside confidence and fund trials in the United States or Europe, where the drug is not yet in registrational testing.

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

March 2017

Dupixent transforms eczema treatment (2017)

The FDA approved dupilumab, sold as Dupixent, an injected biologic for moderate-to-severe atopic dermatitis. It was the first targeted biologic for the disease and cut inflammation for patients who had run out of options.

Then

Patients who failed creams and steroids gained a drug that reliably cleared skin and eased itch.

Now

Dupixent grew into a multibillion-dollar franchise and set the bar every new eczema drug is now measured against.

Why this matters now

Dupixent is a shot, not a pill. Soficitinib's pitch is oral dosing, so its data will be judged against the biologic standard Dupixent set.

September 2021

FDA adds boxed warnings to JAK inhibitors (2021)

The FDA required its strongest boxed warnings on oral JAK inhibitors, flagging risks of serious infections, blood clots, and heart problems. The move followed a large safety study of one such drug in arthritis patients.

Then

The warnings pushed some doctors to reserve oral JAK pills for patients who failed other treatments.

Now

They raised the value of drugs that hit narrower targets, driving interest in selective TYK2 blockers.

Why this matters now

Soficitinib is built to block TYK2 far more than JAK2, aiming to sidestep those risks. Its safety record will decide whether that design pays off.

September 2022

Sotyktu becomes the first approved TYK2 inhibitor (2022)

The U.S. Food and Drug Administration approved Bristol Myers Squibb's deucravacitinib, sold as Sotyktu, for moderate-to-severe plaque psoriasis. It was the first drug to block TYK2, a specific immune-signaling enzyme, rather than the broader JAK family.

Then

Sotyktu gave dermatologists a once-daily pill for psoriasis with a cleaner safety label than older JAK drugs.

Now

It proved the TYK2 target could reach the market and spurred rivals to test the mechanism in other skin diseases.

Why this matters now

Soficitinib works on the same target. Sotyktu shows the class can win approval, but it is not cleared for eczema, the gap InnoCare is chasing.

Sources

(6)
+1
BioSpace HCPLive Dermatology Times GlobeNewswire / InnoCare Pharma InnoCare Pharma BioSpace